Cargando…
三代后的新一代EGFR-TKIs研究进展
Lung cancer has the highest mortality rate in the world. The first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival time and quality of life of patients with non-small cell lung cancer (NSCLC) to some extent. However, after a...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679226/ https://www.ncbi.nlm.nih.gov/pubmed/32773008 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.28 |